Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
Future Cardiol
; 12(4): 405-18, 2016 07.
Article
en En
| MEDLINE
| ID: mdl-27160944
ABSTRACT
Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials.gov NCT00391872) and in patients with a history of myocardial infarction (PEGASUS-TIMI 54; ClinicalTrials.gov NCT01225562). Ongoing trials will provide information on the efficacy and safety of ticagrelor in patients with acute ischemic stroke or transient ischemic attack (SOCRATES; ClinicalTrials.gov NCT01994720), peripheral artery disease (EUCLID; ClinicalTrials.gov NCT01732822) and coronary artery disease in patients with Type 2 diabetes mellitus (THEMIS ClinicalTrials.gov NCT01991795).
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Adenosina
/
Aterosclerosis
/
Síndrome Coronario Agudo
/
Antagonistas del Receptor Purinérgico P2Y
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Future Cardiol
Asunto de la revista:
CARDIOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Suecia